Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus [Phase 2]

View source ↗

Summary

Phase 2 study evaluating a 12-week combination therapy of TMC647055 and TMC435 with and without GSK23336805, plus a pharmacokinetic enhancer, with and without r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• GSK23336805
• Ribavirin (ribavirin)
• TMC435
• TMC647055

Snippet

Sponsor: Janssen R&D Ireland | Conditions: Chronic Hepatitis C | Phase 2 | Status: COMPLETED